Cimzia®
(Rheumatoid arthritis)

Cimzia® (certolizumab pegol) is a PEGylated tumor necrosis factor alpha (TNFα) blocker indicated in the US for:

• treatment of adults with moderately to severely active rheumatoid arthritis.

Warning: risk of serious infections

See full prescribing information for complete boxed warning.

•    Increased risk of serious infections leading to hospitalisation or death including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens
•    Cimzia should be discontinued if a patient develops a serious infection or sepsis
•    Perform test for latent TB; if positive, start treatment for TB prior to starting Cimzia
•    Monitor all patients for active TB during treatment, even if initial latent TB test is negative (5.1)
•    Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which Cimzia is a member (5.2). Cimzia is not indicated for use in pediatric patients.

In Europe, Cimzia®, in combination with methotrexate (MTX), is indicated for the treatment of moderate to severe, active rheumatoid arthritis (RA) in adult patients when the response to disease-modifying antirheumatic drugs (DMARDs) including methotrexate, has been inadequate.

Cimzia® can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.

Cimzia® has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.

Please refer to the Prescribing Information in your country before prescribing.